Press coverage about Arrowhead Pharmaceuticals (NASDAQ:ARWR) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.4114662515548 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Arrowhead Pharmaceuticals, Inc. (ARWR) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
- Technical Analysis Hints Where Arrowhead Pharmaceuticals, Inc. (ARWR) Is Headed In Next Few Days – StockNewsGazette (stocknewsgazette.com)
- Bounding Shares, What’s Next for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)? – FLBC News (flbcnews.com)
- Arrowhead Pharmaceuticals Inc (ARWR) Chaikin Money Flow in Positive Territory – Evergreen Caller (evergreencaller.com)
- NuVasive Inc (NUVA) and Arrowhead Pharmaceuticals Inc (ARWR) Needle Moving on Volume – Evergreen Caller (evergreencaller.com)
A number of research analysts recently issued reports on ARWR shares. ValuEngine downgraded Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Piper Jaffray Companies reiterated a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, August 4th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the stock. The company currently has an average rating of “Hold” and an average price target of $1.80.
Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at 2.12 on Friday. The company’s market capitalization is $158.52 million. The firm has a 50-day moving average price of $1.72 and a 200 day moving average price of $1.77. Arrowhead Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $8.22.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The company had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.29 million. On average, equities analysts predict that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This article was reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.baseball-news-blog.com/2017/08/19/arrowhead-pharmaceuticals-arwr-given-daily-coverage-optimism-rating-of-0-24-updated.html.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.